Researchers have accurately profiled the immune response to COVID-19 in critically ill patients, allowing them to identify six inflammatory molecules as potential targets for COVID-19 treatment.
In this interview we speak to José Javier García from Pivotal about his company´s involvement in a large-scale clinical trial testing the safety and efficacy of hyperimmune convalescent plasma treatment in COVID-19 patients.
Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
Take a look behind the scenes of a recent Future Virology paper, titled ‘Severe acute respiratory syndrome…
Researchers at Scripps Research Institute have used the blood of recovered COVID-19 patients to identify potent antibodies that protect against SARS-CoV-2. The study, published in Science, has shown the antibodies’ successful use in animal models and human cell cultures.
Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.
After analyzing data from SARS survivors, a team of researchers from across the globe has identified an antibody that can inhibit related coronaviruses, including SARS-CoV-2. The antibody, termed S309, is now on an accelerated path towards clinical trials.
Emerging evidence has suggested that B cells and humoral immunity could modulate the immune response to intracellular pathogens. We speak to Babak Javid about his research on this topic and the importance of learning about immune factors in order to develop vaccination strategies and to understand latent TB.
The first strain of flu we encounter during childhood could impact our immune responses to future infections, according to new research.
Researchers from Gladstone Institutes and their partners at Xyphos Biosciences have demonstrated that a cell-based therapy, convertibleCAR®, appears to reduce the latent HIV reservoir in individuals on antiretroviral therapy.
